J
Jérémie Abtan
Researcher at Paris Diderot University
Publications - 9
Citations - 224
Jérémie Abtan is an academic researcher from Paris Diderot University. The author has contributed to research in topics: Clinical endpoint & Acute coronary syndrome. The author has an hindex of 5, co-authored 9 publications receiving 177 citations.
Papers
More filters
Journal ArticleDOI
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry
Arthur Darmon,Deepak L. Bhatt,Yedid Elbez,Victor Aboyans,Sonia S. Anand,Jackie Bosch,Kelley R. Branch,Stuart J. Connolly,Leanne Dyal,John W. Eikelboom,Keith A.A. Fox,Katalin Keltai,Jeffrey L. Probstfield,Salim Yusuf,Jérémie Abtan,Emmanuel Sorbets,Kim A. Eagle,Gregory Ducrocq,Gregory Ducrocq,Philippe Gabriel Steg +19 more
TL;DR: The proportion of patients eligible for the COMPASS trial within the Reduction of Atherothrombosis for Continued Health (REACH) registry is described, suggesting good external applicability, and COMPASS-Eligible patients experienced a higher rate of the primary outcome compared with COMPASS participants in the aspirin alone treatment arm.
Journal ArticleDOI
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention
Matthijs A. Velders,Jérémie Abtan,Dominick J. Angiolillo,Diego Ardissino,Robert A. Harrington,Anne S. Hellkamp,Anders Himmelmann,Steen Husted,Hugo A. Katus,Bernhard Meier,Phillip J. Schulte,Phillip J. Schulte,Robert F. Storey,Lars Wallentin,Philippe Gabriel Steg,Stefan James +15 more
TL;DR: In the subset of patients with STEMI treated with primary PCI, ticagrelor compared with clopidogrel was safe, and efficacy outcomes were consistent with the overall PLATO trial.
Journal ArticleDOI
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial
Jérémie Abtan,P. Gabriel Steg,Gregg W. Stone,Kenneth W. Mahaffey,C. Michael Gibson,Christian W. Hamm,Matthew J. Price,Freddy Abnousi,Jayne Prats,Efthymios N. Deliargyris,Harvey D. White,Robert A. Harrington,Deepak L. Bhatt,Champion Phoenix Investigators +13 more
TL;DR: The benefits and risks of cangrelor were consistent in patients with SA and ACS, and the impact of can grelor on GUSTO severe/moderate bleeding was also similar forSA and ACS.
Journal ArticleDOI
Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry.
Jérémie Abtan,Deepak L. Bhatt,Yedid Elbez,Emmanuel Sorbets,Kim A. Eagle,Christopher M. Reid,Iris Baumgartner,David Wu,Mary E. Hanson,Hakima Hannachi,Puneet K. Singhal,Philippe Gabriel Steg,Philippe Gabriel Steg,Gregory Ducrocq +13 more
TL;DR: Patients with symptomatic peripheral artery disease (PAD) are at high risk of ischemic events, but data about predictors of this risk are limited.
Journal ArticleDOI
Effectiveness of Rescue Percutaneous Balloon Aortic Valvuloplasty in Patients With Severe Aortic Stenosis and Acute Heart Failure.
Marc Eugène,Marina Urena,Jérémie Abtan,Jose-Luis Carrasco,Walid Ghodbane,Patrick Nataf,Alec Vahanian,Dominique Himbert +7 more
TL;DR: Rescue PBAV is safe in patients with CS and high-risk aortic stenosis or refractory pulmonary edema and may improve their dismal prognosis when followed by TAVI or SAVR.